From bench to the bedside: understanding the genetic changes in AML

From bench to the bedside: understanding the genetic changes in AML

VJHemOnc

1 year
42 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, discusses the research carried out by some of his former mentees that identified the IDH1 mutation as a novel therapeutic target in acute myeloid leukemia (AML). As Prof. Ganser explains, the genetic changes that occur in AML are now becoming better understood through enthusiastic young researchers and medical students that are willing to explore exciting new topic areas. This interview was recorded at 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Up Next Autoplay
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Category: Acute Myelogenous Leukemia
2 Views
Cancer-News 5 days
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
7 Views
Cancer-News 1 week
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
Category: Acute Myelogenous Leukemia
15 Views
Cancer-News 1 month
How to Manage MDS Patients who are Ineligible for Transplant
How to Manage MDS Patients who are Ineligible for Transplant
Category: Acute Myelogenous Leukemia
300 Views
obr 5 months
The Recent Wave of Approval in AML
The Recent Wave of Approval in AML
Category: Acute Myelogenous Leukemia
138 Views
obr 5 months
Updated Data on Gilteritinib in AML
Updated Data on Gilteritinib in AML
Category: Acute Myelogenous Leukemia
16 Views
obr 5 months
Latest Data on Uproleselan with Chemotherapy
Latest Data on Uproleselan with Chemotherapy
Category: Acute Myelogenous Leukemia
100 Views
obr 5 months
AML Case: A 54-year-old woman is in remission but MRD+
AML Case: A 54-year-old woman is in remission but MRD+
Category: Acute Myelogenous Leukemia
115 Views
imedex 6 months
Update: New Drugs for AML
Update: New Drugs for AML
Category: Acute Myelogenous Leukemia
177 Views
imedex 6 months
Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And Azacitidine Have Proven As Effective As Standard Dosing
Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And Azacitidine Have Proven As Effective As Standard Dosing
Category: Acute Myelogenous Leukemia
100 Views
Annual-Meeting 6 months